View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2020

University of Georgia’s Covid-19 vaccine shows promise in test models

A Covid-19 vaccine candidate developed by a research team at the University of Georgia (UGA) College of Veterinary Medicine has shown promise in test models.

A Covid-19 vaccine candidate developed by a research team at the University of Georgia (UGA) College of Veterinary Medicine has shown promise in test models.

Previously, the UGA team partnered with the University of Iowa researchers to create a vaccine against MERS-CoV, the coronavirus that causes Middle East Respiratory Syndrome.  UGA research formed the basis for their Covid-19 vaccine development.

The researchers noted that the MERS vaccine could improve immunity in lab studies, giving hope for the vaccine.

Both Covid-19 vaccines build on a viral delivery platform developed by UGA Veterinary Medicine university chair Biao He, who also leads the research team.

The vaccines consist of engineered strains of the parainfluenza virus 5 (PIV5), responsible for kennel cough in dogs. These engineered viruses can also generate the spike proteins found in MERS and SARS-CoV-2, the coronavirus that causes Covid-19.

Following vaccination, cells are infected with the PIV5 virus and then the body begins to produce a defence against the MERS spike proteins generated by the modified virus, said the researchers. This mechanism results in promotion of immunity against infection.

The PIV5 virus has been used due to its safety in humans.

Speaking of the development, He noted: “When your dog is immunised against kennel cough, a similar vaccine is used. After immunisation, the dog will shed this PIV5 for days. If you have a dog, you have been safely exposed to this virus many times.”

Though the vaccine is in the early development stages, the UGA researchers hope that it will pass further tests. The SARS-CoV-2 vaccine could be ready for US regulatory approval by the end of this year.

He added: “We have an opportunity now to use our technology to help people. And, at the University of Georgia, we have the people, and we have the facilities. We have been able to quickly mobilise resources to develop this vaccine.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU